FENC
Fennec Pharmaceuticals Inc
Halal Rating :
Last Price
$5.55
Last updated:
Market Cap
-
7D Change
-4.64%
1 Year Change
-45.85%
Company Overview
Industries
Exchange
Next Earnings Date
Fennec Pharmaceuticals Inc. is a biopharmaceutical company focused on the development of PEDMARK® (sodium thiosulfate injection) for the prevention of platinum-induced ototoxicity in pediatric patients. The company's primary product, PEDMARK®, received FDA approval in September 2022 for preventing hearing loss associated with cisplatin chemotherapy in pediatric patients with localized, non-metastatic solid tumors.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $6.97m | $13.22m | - | $1.05m | 0.00% | 7.91% |
| June 30, 2024 | $7.26m | $12.8m | - | $497000.0 | 0.00% | 3.88% |
| March 31, 2024 | $25.38m | $12.49m | - | $857000.0 | 0.00% | 6.86% |
Company Impact
Help us evaluate Fennec Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.